Drug Profile
Adipose-derived stem cell therapeutics - American CryoStem Corporation
Latest Information Update: 28 Jun 2018
Price :
$50
*
At a glance
- Originator American CryoStem Corporation
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements; Cytokine stimulants; Growth stimulants; Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 28 Jun 2018 No recent reports of development identified for phase-I development in Multiple-sclerosis in Cayman Islands (IV, Injection)
- 18 May 2018 American CryoStem Corporation terminates a phase I trial in Multiple sclerosis in Cayman Islands (IV) (NCT02326935)
- 28 Dec 2017 No recent reports of development identified for phase-I development in Multiple-sclerosis in Cayman Islands (IV, Injection)